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INTRODUCTION 
The purpose of this case is to explore how science-based entrepreneurs identify and evaluate 
opportunities. The case focuses on a biotechnology company, Hart Biologicals, founded in 
2002 by Alby Pattison. In particular, the case explores how Alby, the founder and Managing 
Director, employs effectual decision-making in the pursuit of new opportunities. In addition, 
the case challenges students to consider the impact of effectual decision-making on the 
performance and behaviour of a family firm. The aim is to offer an in-depth account of 
opportunity identification and effectual decision-PDNLQJIURPDQHQWUHSUHQHXU¶VSHUVSHFWLYH, 
providing a contextualised exploration of entrepreneurial experience in practice.  
In the field of innovation research, prior literature has generally focussed on science-based 
innovations and how to render these into commercial products (Tushman & Anderson, 2004). 
In addition, innovation as the translation of ideas into commercial products and services has 
long been considered central to the entrepreneurial process (Drucker, 2002; Kanter, 1984; 
Schumpeter, 1942). A distinction can be made here between invention, something new which 
is conceived or created, and innovation, which is about the application of new ideas and their 
wider diffusion (Khilji, Mroczkowski, & Bernstein, 2006).  Consequently, there is a strong 
link between innovation and entrepreneurship, and the two are often simultaneous as new 
opportunities are identified and exploited in the pursuit of profits and the drive for growth 
(Tidd & Bessant, 2011). However, the decision-making processes of entrepreneurs ± and how 
they identify, evaluate and pursue business opportunities ± is considered to be a poorly 
understood phenomenon (Shane, 2012), particularly in the context of science-based business 
(Pisano, 2010). 
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Understanding effectual decision-making 
Causal ± or predictive ± logic is where the entrepreneur first selects a goal and then chooses 
between a given set of means, or seeks to acquire such means to achieve the selected goal 
(Sarasvathy, 2001). An example used by Sarasvathy (2001) is that of the cook who creates a 
meal from a recipe (causal logic) versus the cook who envisages potential meals from the 
ingredients that are to hand (effectual logic). Thus, Sarasvathy (2009, p. 73) suggests: 
³&DXVDOVWUDWHJLHVDUHXVHIXOZKHQWKHIXWXUHLVSUHGLFWDEOHJRDOVDUHFOHDUDQGWKH
environment is independent of our actions; effectual strategies are useful when the 
future is unpredictable, goals are unclear and the environment is driven by human 
DFWLRQ´ 
Effectual decision-making is, therefore, closely associated with opportunity recognition 
(Dew, Read, Sarasvathy, & Wiltbank, 2009), a central concept in the field of 
entrepreneurship. Entrepreneurship research has focused on attempts to understand how 
individual entrepreneurs make decisions under conditions of uncertainty (Alvarez & Barney, 
2005). Effectual decision-making is considered to be an essential part of the entrepreneurial 
process of undertaking a new venture (Zivdar, Imanipour, Talebi, & Hosseini, 2017), such as 
an acquisition, and helps us to understand how entrepreneurs identify, evaluate and pursue 
new opportunities (Pattinson, 2016). The traditional view of decision-making in organisations 
adopts a rational view where the goal is set from the beginning and the means are gathered in 
order to fulfil the goal (Eisenhardt & Zbaracki, 1992). Sarasvathy (2001), on the other hand, 
contends that entrepreneurs adopt an alternative logic ± effectuation ± when the means are 
known to them, but not the goals.  
The concept of effectuation was first developed by Sarasvathy and introduced as an 
alternative decision-making logic used by serial entrepreneurs (Sarasvathy, 2001; Sarasvathy, 
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Dew, Velamuri, & Venkataraman, 2003). Under conditions of uncertainty Sarasvathy (year) 
considers how entrepreneurs leverage three main assets, i) their prior knowledge, or know-
how, ii) their identity, or who they are, and iii) their networks, or who they know. By 
leveraging these assets, the entrepreneur brings together the goals and the means, resulting in 
new ideas, partnerships, products and markets that could not have been foreseen at the start of 
the process. The logic of effectual decision-making has been linked to entrepreneurial 
capabilities (Wilson & Martin, 2015) and is considered to be a significant factor affecting 
start-up decisions. Investment in new ideas are also based on the principle of affordable loss, 
which means that the entrepreneur only commits to an investment that she/he can afford to 
lose, and to which the process has to be adapted (Sarasvathy, 2009).  
According to Sarasvathy (2001), effectuation is not better than causation, but it is more 
suitable in situations when the means are limited and the future is uncertain. Effectuation 
differs from causation, where there is a predetermined goal and the process to achieve it is 
planned in accordance with a set of given resources. Sarasvathy (2001) argues that such 
causal logic does not suit entrepreneurial processes that are inherently characterised by 
uncertainties and risks. This means that the entrepreneur is more likely to use a causal 
approach when they have more resources, or act within a large corporation and/or in a stable 
environment. She argues that this approach has the benefit of being less risky because the 
entrepreneur will only invest what they can afford to lose. It is more likely to yield 
unexpected results (Kalinic, Sarasvathy, & Forza, 2014). 
HART BIOLOGICALS 
Prior to establishing Hart Biologicals3 Alby Pattison had been an experienced senior 
biochemist working for a global biotechnology company. However, after more than 20 years 
                                                          
3 More details of the company can be found on its website: https://www.hartbio.co.uk 
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working in a large organisation, Alby decided the time was right to start his own business, as 
he explains: 
³5HDOO\WKHEXVLQHVVVWDUWHGEHFDXVH,¶GLGHQWLILHGDQRSSRUWXQLW\DQG,ZDV
interested in taking it forward, so we set off as a one product company in 2002´ 
6RLQ$OE\¶VQHZFRPSDQ\ZDVIRXQGHG+DUW Biologicals is a biotechnology 
FRPSDQ\PDQXIDFWXULQJDUDQJHRIµLQ-YLWUR¶4 diagnostic products for use in the detection, 
prevention, and monitoring of medical conditions related to haemostasis and platelet function 
(Hart Biologicals, 2018) . Used in combination with an electronic instrument, WKHFRPSDQ\¶V
products can determine how quickly or slowly blood clots for patients being treated with 
warfarin, a medication used as an anticoagulant (blood thinner). Hart Biologicals currently 
employs 12 staff and the company is currently involved in all areas of coagulation and 
platelet aggregation. The company turnover has risen from £100,000 in 2003 to £2.6 million 
in 2017. 
Company background 
Hart Biologicals started in a small incubator unit on an industrial park, employing just three 
PHPEHUVRIVWDII7KHFRPSDQ\LQLWLDOO\PDQXIDFWXUHGDVLQJOHSURGXFWµ0DQFKHVWHU
&DSLOODU\5HDJHQW¶DSURGXFWUHTXLUHGIRUWKHHIIHFWLYHPDQDJHPHnt of patients being treated 
with a product called Warfarin. Warfarin is an anticoagulant (blood thinner) and has a wide 
range of applications, including treating patients who have had heart valve replacement 
surgery, deep vein thrombosis, and sufferers of atrial fibrillation (irregular heart beat). There 
are about one and a half million people in the UK who have been prescribed Warfarin and 
they must be monitored regularly. Manchester Capillary Reagent provides an effective testing 
                                                          
4  ?/Ŷ-ǀŝƚƌŽ ?ƌĞĨĞƌƐƚŽƚŚĞtechnique of performing a given procedure in a controlled environment outside of a 
living organism (see, https://mpkb.org/home/patients/assessing_literature/in_vitro_studies). 
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system for monitoring the administration of Warfarin to patients undergoing such 
anticoagulant therapy. Alby had purchased the rights to manufacture and distribute 
Manchester Capillary Reagent from the Thrombosis Reference Centre at Withington 
Hospital, Manchester because:  
³The [Withington] hospital was closing and merging with the Wythenshawe hospital 
LQ0DQFKHVWHUDQGWKH\FRXOGQ¶WWDNHPDQXIDFWXULQJZLWKWKHP«Dnd so I ended up 
on their doorstep with the knowledge of how to make the product, [and] the 
knowledge of the technology around it´ 
Alby knew that the product offered a cost-effective solution to the therapeutic monitoring 
of Warfarin (also known under the brand names Coumadin, Jantoven, Marevan, Lawarin, 
Waren and Warfant). Due to current medical trends, hand held monitors have been developed 
WRGHWHUPLQHDSDWLHQW¶V:DUIDULQGRVDJHcalled the International Normalised Ratio (INR) 
value) using a finger-prick blood test. However, these devices are expensive and the freeze-
dried strips these devices use to PHDVXUHWKHSDWLHQW¶VEORRGVDPSOHFDQFRVWEHWZHHQGBP 
£2-3 per test. The Manchester Capillary Reagent, on the other hand, uses a wet chemistry 
method rather than a freeze-dried strip. Due to this limitation, the cost of a test using 
Manchester Capillary Reagent costs around £0.10 per test. This means that in the period of 
just over a year Manchester Capillary Reagent becomes much more cost-effective to use. It 
still requires a finger-prick blood test and can be used by nurses in a residential setting, as 
well as in *3¶VVXUJHULHVDQGKRVSLWDOV, which also makes it easy to administer.  
Serving a niche market 
Hart Biologicals was initially set up to supply Warfarin, a specialised innovative product, to a 
very specific, niche market, as Alby explains: 
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³Hart was set up to serve a very niche market and the business was set up specifically 
to be a niche business. The sector, certainly in Western Europe, is dominated by 5 or 
6 huge multinationals. If a small company like us tried to go head to head with the big 
JX\VZH¶GEHEHDWHQRQSULFHHYHU\WLPH6RZHGHFLGHGWRJRIRUWKHEXVLQHVVWKDW
the big guys are really not interested in´ 
+RZHYHUIROORZLQJWKHFRPSDQ\¶VLQLWLDOVXFFHVVDVD:DUIDULQPDQXIDFWXUHUAlby soon 
saw the need to broaden its range of products to meet increasing market demand. This meant 
not only increasing the company's staffing levels due to the increased demand for products, 
but it also highlighted the need to ensure that the best facilities were available in order to 
broaden the product range. So, in August 2009, Hart Biologicals moved to purpose-built 
premises. Within the move, a new fully automated bespoke freeze dryer was purchased which 
allowed +DUW%LRORJLFDO¶VVFLHQWLVWVWRFRQWUROWKHGHYHORSPHQWDQGSURGXFWLRQSURFHVVZLWK
upmost precision. Hart Biologicals are currently involved in all areas of Coagulation and 
Platelet Aggregation and produce a range of products for that market. It has built an extensive 
global network of distributors from South America to Asia.  
Organic growth or acquisition? 
7RGDWH+DUW%LRORJLFDOVKDGSXUVXHGDVWUDWHJ\RIRUJDQLFJURZWKVHOOLQJLWVµRZQEUDQG¶
products to a niche market, in addition to manufacturing branded products on behalf of other 
companies. However, Alby had not set out to be a contract manufacturer. His original 
intention has been to produce a range of µRZQEUDQG¶products that would sell under the 
EDQQHURIµ+DUW%LRORJLFDOV¶DQGKHZRXld have been satisfied with pursuing that opportunity. 
Nevertheless, when other companies started seeking +DUW¶Vscientific expertise and, 
considering how aggressively that had enabled the business to grow, Alby had been forced to 
recognise the potential of the contract manufacturing side of his business. He now felt he had 
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to focus on these two strands of the business. The first strand is Hart Biological¶V own-
labelled products which are sold through various distribution networks. The second strand, 
the contract manufacturing work, is where the company sells its clinical capabilities to other 
firms. As Alby explains: 
³On the contract manufacturing side things have gone incredibly well, the own label 
materials are growing quite well, but the contract manufacturing really exceeded all 
H[SHFWDWLRQV:H¶UHQRZZRUNLQJLQWKH86$WZRELJFRPSDQLHVLQ*HUPDQ\DQGZH
manufacture products for a number of national quality schemes around the world. 
Our name is getting more and more known out there´ 
Alby is now looking to expand +DUW¶Vrange of products in order to grow the business and 
he has spotted a potential opportunity to acquire a smaller firm: 
³:H¶YHJRWDSRWHQWLDODFTXLVLWLRQLQRXUVLJKWVDWWKHPRPHQW$JDLQLW¶VDV\PELRWLF
EXVLQHVV,W¶VVWLOOZRUNLQJLQWKHKDHPDWRORJ\DUHDEXWLWGRHVQ¶WFRPSHWHZLWKRXU
SURGXFWVLWDFWXDOO\DGGVWRRXUSURGXFWV,W¶VDYHU\VLPLODUEXVLQHVV,W¶VRZQHGE\D
guy who used to work in hospital labs, his brother works with him, there are four of 
WKHPDQG,¶OOEHKRQHVW± it makes money hand over fist, it really does´  
Having identified that the potential acquisition was likely to be very profitable, Alby had 
already spoken to the bank about raising the capital required for the acquisition. However, 
over the years Hart Biologicals had grown organically, through increased sales based on its 
growing reputation, and this had allowed staff to grow into their roles and gain experience 
gradually. +DUWLVDOVRYHU\PXFKDIDPLO\ILUP$OE\¶VEURWKHUDQHQJLQHHULVWKH7HFKQLFDO
Manager, and $OE\¶Vwife manages the µIURQWGHVN¶ and administration team. Alby is excited 
by the prospect of the acquisition but, at the same time, he is concerned that such a new 
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direction, although signalling the biggest and most rapid period of growth and change for the 
company, would also signal the end of Hart Biologicals as a family firm.    
SUMMARY 
Alby Pattison now has an important decision to make regarding the future direction of Hart 
Biologicals. Should he continue to pursue organic growth through increased sales or to go 
ahead with the proposed acquisition of another firm? The proposed acquisition will help the 
EXVLQHVVJURZPRUHTXLFNO\DQGZLOODGGQHZSURGXFWVWR+DUW¶VJURZLQJUDQJHRIµLQ-YLWUR¶
diagnostic products. However, acquisition strategies present a risk for small firms in terms of 
integrating the acquired firm into their current strategy.  This case is useful in highlighting 
how effectual decision-making is employed by the entrepreneur to identify, evaluate, and 
pursue this new opportunity. It advances our understanding of effectual decision-making in 
the context of a science-based small firm. 
Questions 
1. 7RZKDWH[WHQWZDV$OE\¶VGHFLVLRQWRVHWXS+DUW%LRORJLFDOVDQH[DPSOHRIHIIHFWXDO
decision-making?  
2. Is organic growth a suitable strategy for Hart Biologicals, a science-based small firm 
operating in a niche market?  
3. What are the potential advantages/disadvantages for Hart Biologicals in pursuing a 
strategy based on acquisition, rather than organic growth? 
4. +RZGRHV$OE\¶VSURSRVHGDFTXLVLWLRQILWZLWKHart Biologicals serving a niche market? 
5. How might the potential acquisition impact on the growth of a family firm such as Hart 
Biologicals? 
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TEACHING NOTE  
1 Summary of the case 
Hart Biologicals is engaged in the research, development, manufacture, and marketing of a 
range of µin-vitro¶ diagnostic products for use in the detection, prevention, and monitoring of 
a number of medical conditions related to haemostasis and platelet function. This case study 
focuses on entrepreneurial decision-making and the firm¶s approach to business growth. The 
company has pursued a strategy of organic growth through increased sales but is now 
considering the acquisition of a firm that produces a complimentary product that would add 
to its existing range of products.     
2 Teaching objectives and target audience 
The key issue in this case study is whether the company should press ahead with a proposed 
acquisition. There is also a secondary issue regarding whether it should continue to produce 
its own-EUDQGHGSURGXFWVRUIRFXVRIWKHYHU\OXFUDWLYHµFRQWUDFWPDQXIDFWXULQJ¶side of the 
business. This case study will enable students to understand different approaches to 
entrepreneurial decision-making, performance and behaviour of a family firm.  This case 
study is aimed at both undergraduate and postgraduate students studying strategy and 
entrepreneurship. There are four learning objectives: 
a) The case study provides a starting point for students to engage in evidence-informed 
discussions about how science-based entrepreneurs identify and evaluate 
opportunities.   
b) The case study also enables students to consider how science-based entrepreneurs 
pursue new opportunities. 
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c) The case study allows students to engage in a broader discussion about approaches to 
entrepreneurial decision-making.  
d) The case challenges students to consider the impact of effectual decision-making on 
the performance and behaviour of a family firm. 
3 Teaching approach and strategy 
This case study can be used as the starting point for students to discuss different approaches 
to entrepreneurial decision-making, performance and behaviour of a family firm. It allows the 
application of classroom-based theory to be applied to a real-life situation and encourages 
active participation in the learning process. The main theoretical points to highlight when 
using the cases study centre round the concept of entrepreneurial decision-making. The case 
study places entrepreneurial decision-making within the context of science-based business 
and provides an opportunity for students to gain insights into how entrepreneurs identify, 
evaluate and pursue new opportunities. The case allows students to engage in a broader 
discussion about entrepreneurial approaches to strategy building and development in small 
firms.  
Wherever possible, the classroom should be arranged with desks in a semicircle, or a 
similar layout, that allows students to face each other and work together in small groups. This 
layout will help to facilitate a direct exchange of views between students. Teaching this case 
begins by asking students to read and think about the case ± either at the start of, or prior to 
class ± depending on the length of the seminar/tutorial. A 5-10 minute introduction to the 
case by the lecturer might then be useful before beginning any discussion. The introduction 
should explain $OE\¶VGLOHPPD; whether to continue to continue to pursue organic growth 
through increased sales, or to go ahead with the proposed acquisition of another firm. The 
lecturer might wish to present the potential alternatives to the proposed acquisition and the 
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challenges associated with each of choice, i.e. organic growth or acquisition. The goal of the 
case is not to select the correct choice for Hart Biologicals, but rather to understand the 
challenges inherent in entrepreneurial decision-making and how small business owners can 
mitigate any associated risks.  
Once the introduction is complete, the lecturer might wish to break the class up into teams 
of three to five students, depending on student numbers. The teams should discuss and 
summarise their answers to each of the questions presented in the case study and choose one 
UHSUHVHQWDWLYHWRSUHVHQWDVXPPDU\RIWKHWHDP¶VDQVZHUVWRthe class. The lecturer should 
work to move the discussion past a listing of challenges to an identification of the potential 
outcomes of the available choices. To conclude the session, the lecturer might consider 
asking students to report back ± either in their groups or individually ± to summarise what 
they consider to be the main learning outcomes of the session. Alternatively, the lecturer 
could ask them to take a few minutes to summarise their own thoughts about the main points 
raised in the case. It is also important to ask students to evaluate the usefulness of the case in 
their studies in order to help students evaluate their own learning as well as to help the 
lecturer to evaluate the usefulness of the case and make amendments where necessary. 
4 Analysis 
Students should be reassured that there are no right or wrong answers, but rather the case 
study provides a springboard for discussion about the main issues raised in the case. 
However, students are challenged to think about a real-life scenario where entrepreneurial 
decision-making by the main protagonist (Alby Pattison) can be analysed in detail. More 
specifically, students should consider the following point in their answers to the questions 
posed:   
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7RZKDWH[WHQWZDV$OE\¶VGHFLVLRQWRVHWXSHart Biologicals an example of effectual 
decision-making?  
6WXGHQWVVKRXOGEHDEOHWRLGHQWLI\WKDW$OE\¶VGHFLVLRQWRVHWXS+DUW%LRORJLFDOVLVDn 
example of effectual decision-making. From the case material, students should be able to 
clearly recognise that Alby used effectual decision-making to identify an opportunity and 
acted on this by setting up Hart Biologicals as a one-product company. Students might also 
identify that, in recognising the potential of the contract manufacturing side of the business, 
Alby was again exercising an effectual approach to decision making. 
Is organic growth a suitable strategy for Hart Biologicals, a science-based small firm 
operating in a niche market??  
Students should be able to recognise that organic growth is a slower but more manageable 
form of growth for a small firm. However, Alby clearly has ambitions beyond this objective, 
and is actively exploring an acquisition opportunity. This is a good display of how effectual 
decision-making enables an entrepreneur to identify, evaluate and, pursue new potential 
growth opportunities. Student discussions here might include consideration of whether Hart 
Biologicals VKRXOGIRFXVRQLWVµRZQEUDQG¶products or continue with the very lucrative 
µFRQWUDFWPDQXIDFWXULQJ¶VLGHRIWKHEXVLQHVV 
What are the potential advantages/disadvantages for Hart Biologicals in pursuing a strategy 
based on acquisition, rather than organic growth? 
Students should be able to recognise that effectual decision-making is a flexible approach to 
decision-making that enables entrepreneurs to take advantage of potential growth 
opportunities as they arise. In addition to financial gain, students might also identify a 
number of other advantages including speed of growth, increased market power/share, new 
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resources and competencies, and reduced market entry barriers. The main disadvantages 
might include increased costs, lack of cultural fit, unrelated diversification, and distraction 
from its core business. 
+RZGRHV$OE\¶VSURSRVHGDFTXLVLWLRQILWZLWK+DUW%LRORJLFDOVVHUYLQJa niche market? 
Students should be able to distinguish between niche and mass markets and suggest some 
UHDVRQVZK\$OE\¶VSURSRVHGDFTXLVLWLRQPLJKWEHDWYDULDQFHZLWKWKHILUP¶VFXUUHQW
strategy, or with serving a niche market. Equally, students might consider that the acquisition 
creates QHZRSSRUWXQLWLHVWRH[SDQG+DUW¶VSURGXFWUDQJHDQGto provide access to new 
markets, enabling it to serve a wider customer base. Students might want to explore the Hart 
Biologicals website (https://www.hartbio.co.uk) in order to find out more about the company. 
How might the potential acquisition impact on the growth of a family firm like Hart 
Biologicals? 
Hart Biologicals is a family-run firm and the case study asks students to consider the 
implications of the potential acquisition on the future performance and behaviour of a family 
firm. Students might, therefore, be encouraged to consider whether family firms are able to 
make better acquisitions than, for example, non-family firms, and why this might be. 
5 Feedback 
Please take time to reflect and consider how the case worked in different situations (for 
example, with different student groups, or on different modules). The case has been tested 
and has been an effective part of teaching entrepreneurship and strategy to a range of 
undergraduate and postgraduate programmes, including Business Management, International 
Business Management, Marketing, and Business and Entrepreneurship. More specifically, it 
has been used to support the teaching of small seminars groups on modules such as 
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µInternational Strategic Challenges¶µEntrepreneurial Leadership¶DQGµInternational 
Business: Growth Strategies and Resourcing¶This case could also be used on other 
programmes of study such as MDVWHU¶VGHJUHHVLQHQWHUSULVHHQWUHSUHQHXUVKLSDQGRU
innovation, MBA courses, or with doctoral students. Potentially, the case is suitable for use as 
a written assessment or for an examination, role-playing, or for other purposes. 
6 References (including additional suggested reading) 
Aiginger, K. and Tichy, G. (1991) Small firms and the merger mania. Small Business 
Economics, 3(2), 83-101. 
Baron, R. A. (2009). Effectual versus predictive logics in entrepreneurial decision-making: 
Differences between experts and novices: Does experience in starting new ventures 
FKDQJHWKHZD\HQWUHSUHQHXUVWKLQN"3HUKDSVEXWIRUQRZ³FDXWLRQ´LVHVVHQWLDO
Journal of Business Venturing, 24(4), 310-315. 
Gabrielsson, J., & Politis, D. (2011). Career motives and entrepreneurial decision-making: 
examining preferences for causal and effectual logics in the early stage of new 
ventures. Small Business Economics, 36(3), 281-298. 
Maine, E., Soh, P. H., & Dos Santos, N. (2015). The role of entrepreneurial decision-making 
in opportunity creation and recognition. Technovation, 39, 53-72. 
Mitra, J. (2007) Life science innovation and the restructuring of the pharmaceutical industry: 
Merger, acquisition and strategic alliance behaviour of large firms. Technology 
Analysis & Strategic Management, 19(3), 279-301. 
Pasanen, M. (2007) SME growth strategies: organic or non-organic?. Journal of Enterprising 
Culture, 15(4), 317-338.  
18 
 
Penrose, E. (1997) The theory of the growth of the firm, in Foss, N.J. Resources, firms, and 
strategies: a reader in the resource-based perspective, Oxford University Press: 
Oxford, pp.27-39. 
Perry, J. T., Chandler, G. N., & Markova, G. (2012). Entrepreneurial effectuation: a review 
and suggestions for future research. Entrepreneurship Theory and Practice, 36(4), 
837-861. 
Reymen, I. M., Andries, P., Berends, H., Mauer, R., Stephan, U., & Burg, E. (2015). 
Understanding dynamics of strategic decision-making in venture creation: a process 
study of effectuation and causation. Strategic Entrepreneurship Journal, 9(4), 351-
379. 
Shepherd, D. A., Williams, T. A., & Patzelt, H. (2015). Thinking about entrepreneurial 
decision-making: Review and research agenda. Journal of Management, 41(1), 11-46. 
